Enlivex Therapeutics Ltd. (NASDAQ:ENLV – Get Free Report) was the recipient of a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 236,400 shares, a decline of 9.6% from the March 15th total of 261,500 shares. Based on an average daily trading volume, of 88,300 shares, the days-to-cover ratio is currently 2.7 days.
Institutional Trading of Enlivex Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of ENLV. Bank of America Corp DE grew its stake in shares of Enlivex Therapeutics by 87.0% in the first quarter. Bank of America Corp DE now owns 6,163 shares of the company’s stock worth $34,000 after purchasing an additional 2,867 shares during the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of Enlivex Therapeutics in the first quarter worth $68,000. UBS Group AG grew its stake in shares of Enlivex Therapeutics by 73.4% in the third quarter. UBS Group AG now owns 31,871 shares of the company’s stock worth $136,000 after purchasing an additional 13,490 shares during the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Enlivex Therapeutics by 89.6% in the first quarter. Jane Street Group LLC now owns 52,507 shares of the company’s stock worth $294,000 after purchasing an additional 24,807 shares during the last quarter. Institutional investors own 1.02% of the company’s stock.
Enlivex Therapeutics Stock Performance
Shares of NASDAQ ENLV traded up $0.03 during midday trading on Wednesday, reaching $1.48. 388,662 shares of the company were exchanged, compared to its average volume of 167,805. The stock’s 50-day moving average price is $3.41 and its 200-day moving average price is $2.55. Enlivex Therapeutics has a one year low of $1.15 and a one year high of $4.59.
Analyst Ratings Changes
Read Our Latest Research Report on ENLV
About Enlivex Therapeutics
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.
Featured Stories
- Five stocks we like better than Enlivex Therapeutics
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- United Airlines Soars on Earnings Beat
- How to Buy Cheap Stocks Step by Step
- J.B. Hunt Hits the Skids: Lower Prices to Come
- How to Use the MarketBeat Dividend Calculator
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.